CADM1 and MAL methylation status in cervical scrapes is representative of the most severe underlying lesion in women with multiple cervical biopsies

International Journal of Cancer

Volumn 138, Issue 2, 2016, Pages 463-471

  Van Baars, Romy ^a   Van Der Marel, Jacolien ^a   Snijders, Peter J F ^b   Rodriquez Manfredi, Agata ^c   Ter Harmsel, Bram ^d   Van Den Munckhof, Henk A M ^a   Ordi, Jaume ^e   Del Pino, Marta ^c   Van De Sandt, Miekel M ^a   Wentzensen, N ^f   Meijer, Chris J L M ^b   Quint, Wim G V ^a  

^a DDL DIAGNOSTIC LABORATORY   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c HOSPITAL CLÍNIC   (Spain)

^d Roosevelt Kliniek   (Netherlands)

^e CENTRE FOR RESEARCH IN ENVIRONMENTAL EPIDEMIOLOGY CREAL   (Spain)

^f NATIONAL CANCER INSTITUTE   (United States)

Author keywords

cervical cancer; cervical intraepithelial neoplasia; DNA methylation; human papillomavirus; tumour suppressor genes

Indexed keywords

CADM1 PROTEIN, HUMAN; CELL ADHESION MOLECULE; IMMUNOGLOBULIN; INTERLEUKIN 1 RECEPTOR; MEMBRANE PROTEIN; TIRAP PROTEIN, HUMAN;

ADULT; AGED; COLPOSCOPY; DNA METHYLATION; FEMALE; GENETICS; HUMAN; MIDDLE AGED; MULTIPLEX POLYMERASE CHAIN REACTION; PATHOLOGY; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX TUMOR; VAGINA SMEAR; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; CELL ADHESION MOLECULES; CERVICAL INTRAEPITHELIAL NEOPLASIA; COLPOSCOPY; DNA METHYLATION; FEMALE; HUMANS; IMMUNOGLOBULINS; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; MULTIPLEX POLYMERASE CHAIN REACTION; RECEPTORS, INTERLEUKIN-1; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS; YOUNG ADULT;

EID: 84955654586     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29706     Document Type: Article

References (40)

1. Bosch FX, Lorincz A, Munoz N, et al., The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002; 55: 244-65.
2. Walboomers JM, Jacobs MV, Manos MM, et al., Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189: 12-19.
3. Doorbar J, Quint W, Banks L, et al., The biology and life-cycle of human papillomaviruses. Vaccine 2012; 30 (Suppl 5): F55-F70.
4. Ostor AG., Natural history of cervical intraepithelial neoplasia: a critical review. Int J Gynecol Pathol 1993; 12: 186-92.
5. Doorbar J., Molecular biology of human papillomavirus infection and cervical cancer. Clin Sci (Lond) 2006; 110: 525-41.
6. McCredie MR, Sharples KJ, Paul C, et al., Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study. Lancet Oncol 2008; 9: 425-34.
7. Vink MA, Bogaards JA, van Kemenade FJ, et al., Clinical progression of high-grade cervical intraepithelial neoplasia: estimating the time to preclinical cervical cancer from doubly censored national registry data. Am J Epidemiol 2013; 178: 1161-9.
8. Bierkens M, Wilting SM, van Wieringen WN, et al., Chromosomal profiles of high-grade cervical intraepithelial neoplasia relate to duration of preceding high-risk human papillomavirus infection. Int J Cancer 2012; 131: E579-E585.
9. Herman JG, Baylin SB., Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 2003; 349: 2042-54.
10. Jones PA, Gonzalgo ML., Altered DNA methylation and genome instability: a new pathway to cancer? Proc Natl Acad Sci USA 1997; 94: 2103-5.
11. Bierkens M, Hesselink AT, Meijer CJ, et al., promoter methylation levels in hrHPV-positive cervical scrapes increase proportional to degree and duration of underlying cervical disease. Int J Cancer 2013; 133: 1293-9.
12. Overmeer RM, Henken FE, Bierkens M, et al., Repression of MAL tumour suppressor activity by promoter methylation during cervical carcinogenesis. J Pathol 2009; 219: 327-36.
13. Overmeer RM, Louwers JA, Meijer CJ, et al., Combined CADM1 and MAL promoter methylation analysis to detect (pre-)malignant cervical lesions in high-risk HPV-positive women. Int J Cancer 2011; 129: 2218-25.
14. Hesselink AT, Heideman DA, Steenbergen RD, et al., Combined promoter methylation analysis of CADM1 and MAL: an objective triage tool for high-risk human papillomavirus DNA-positive women. Clin Cancer Res 2011; 17: 2459-65.
15. Bekkers RL, Melchers WJ, Bulten J, et al., Localized distribution of human papillomavirus genotypes in the uterine cervix. Eur J Gynaecol Oncol 2002; 23: 203-6.
16. Yang HP, Zuna RE, Schiffman M, et al., Clinical and pathological heterogeneity of cervical intraepithelial neoplasia grade 3. PLoS One 2012; 7: e29051.
17. Quint W, Jenkins D, Molijn A, et al., One virus, one lesion-individual components of CIN lesions contain a specific HPV type. J Pathol 2012; 227: 62-71.
18. van der Marel J, van Baars R, Quint WG, et al., The impact of human papillomavirus genotype on colposcopic appearance: a cross-sectional analysis. BJOG 2014; 121: 1117-26.
19. Jeronimo J, Long LR, Neve L, et al., Digital tools for collecting data from cervigrams for research and training in colposcopy. J Low Genit Tract Dis 2006; 10: 16-25.
20. Kleter B, van Doorn LJ, ter Schegget J, et al., Novel short-fragment PCR assay for highly sensitive broad-spectrum detection of anogenital human papillomaviruses. Am J Pathol 1998; 153: 1731-9.
21. Kleter B, van Doorn LJ, Schrauwen L, et al., Development and clinical evaluation of a highly sensitive PCR-reverse hybridization line probe assay for detection and identification of anogenital human papillomavirus. J Clin Microbiol 1999; 37: 2508-17.
22. Quint WG, Scholte G, van Doorn LJ, et al., Comparative analysis of human papillomavirus infections in cervical scrapes and biopsy specimens by general SPF(10) PCR and HPV genotyping. J Pathol 2001; 194: 51-8.
23. Luo W, Yang H, Rathbun K, et al., Detection of human immunodeficiency virus type 1 DNA in dried blood spots by a duplex real-time PCR assay. J Clin Microbiol 2005; 43: 1851-7.
24. van Doornum GJ, Guldemeester J, Osterhaus AD, et al., Diagnosing herpesvirus infections by real-time amplification and rapid culture. J Clin Microbiol 2003; 41: 576-80.
25. Livak KJ, Schmittgen TD., Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta C(T)) method. Methods 2001; 25: 402-8.
26. Moscicki AB, Ma Y, Wibbelsman C, et al., Rate of and risks for regression of cervical intraepithelial neoplasia 2 in adolescents and young women. Obstet Gynecol 2010; 116: 1373-80.
27. Brentnall AR, Vasiljevic N, Scibior-Bentkowska D, et al., A DNA methylation classifier of cervical precancer based on human papillomavirus and human genes. Int J Cancer 2014; 135: 1425-32.
28. Clarke MA, Wentzensen N, Mirabello L, et al., Human papillomavirus DNA methylation as a potential biomarker for cervical cancer. Cancer Epidemiol Biomarkers Prev 2012; 21: 2125-37.
29. Cuzick J, Bergeron C, von Knebel Doeberitz M, et al., A new technologies and procedures for cervical cancer screening. Vaccine 2012; 30 (Suppl 5): F107-F116.
30. Eijsink JJ, Lendvai A, Deregowski V, et al., A four-gene methylation marker panel as triage test in high-risk human papillomavirus positive patients. Int J Cancer 2012; 130: 1861-9.
31. Hansel A, Steinbach D, Greinke C, et al., A promising DNA methylation signature for the triage of high-risk human papillomavirus DNA-positive women. PLoS One 2014; 9: e91905.
32. Wentzensen N, Sherman ME, Schiffman M, et al., Utility of methylation markers in cervical cancer early detection: appraisal of the state-of-the-science. Gynecol Oncol 2009; 112: 293-9.
33. Wilting SM, van Boerdonk RA, Henken FE, et al., Methylation-mediated silencing and tumour suppressive function of hsa-miR-124 in cervical cancer. Mol Cancer 2010; 9: 167.
34. Wilting SM, Steenbergen RD, Tijssen M, et al., Chromosomal signatures of a subset of high-grade premalignant cervical lesions closely resemble invasive carcinomas. Cancer Res 2009; 69: 647-55.
35. Steenbergen RD, Snijders PJ, Heideman DA, et al., Clinical implications of (epi)genetic changes in HPV-induced cervical precancerous lesions. Nat Rev Cancer 2014; 14: 395-405.
36. Wentzensen N, Schiffman M, Dunn ST, et al., Grading the severity of cervical neoplasia based on combined histopathology, cytopathology, and HPV genotype distribution among 1,700 women referred to colposcopy in Oklahoma. Int J Cancer 2009; 124: 964-9.
37. Petry kU, Luyten A, Scherbring S., Accuracy of colposcopy management to detect CIN3 and invasive cancer in women with abnormal screening tests: results from a primary HPV screening project from 2006 to 2011 in Wolfsburg, Germany. Gynecol Oncol 2013; 128: 282-7.
38. Pretorius RG, Zhang WH, Belinson JL, et al., Colposcopically directed biopsy, random cervical biopsy, and endocervical curettage in the diagnosis of cervical intraepithelial neoplasia II or worse. Am J Obstet Gynecol 2004; 191: 430-4.
39. Feng Q, Balasubramanian A, Hawes SE, et al., Detection of hypermethylated genes in women with and without cervical neoplasia. J Natl Cancer Inst 2005; 97: 273-82.
40. Reesink-Peters N, Wisman GB, Jeronimo C, et al., Detecting cervical cancer by quantitative promoter hypermethylation assay on cervical scrapings: a feasibility study. Mol Cancer Res 2004; 2: 289-95.